Charlesworth E N, Kagey-Sobotka A, Norman P S, Lichtenstein L M
Department of Medicine, Johns Hopkins University School of Medicine, Good Samaritan Hospital, Baltimore, Md 21239.
J Allergy Clin Immunol. 1989 May;83(5):905-12. doi: 10.1016/0091-6749(89)90104-8.
A new H1 antihistamine, cetirizine, was studied to determine its effects on mediators and cellular infiltration during the cutaneous late-phase response (LPR). Ten ragweed-allergic subjects, who had previously demonstrated a cutaneous LPR, were examined in a double-blind, crossover study. Either cetirizine, 20 mg, or placebo was administered orally once daily for 2 days before and the morning of placement of a skin chamber overlying an unroofed heat/suction-induced blister to which was added antigen or buffer. Skin test erythema was significantly reduced by cetirizine at 15 minutes, 2 hours, and 4 hours by 56%, 40%, and 39%, respectively (all, p less than or equal to 0.01), but by 6 and at 8 hours, the cutaneous erythema was not significantly lessened. Histamine release was not altered by cetirizine treatment, but prostaglandin D2 (PGD2) production, which peaked at 3 to 5 hours, was clearly reduced by cetirizine treatment, being lower at all time points during the reaction; this was significant by analysis of variance (p less than or equal to 0.04). The inhibition was most marked during the fifth hour of the reaction when there was a 50% suppression of the PGD2 level by cetirizine (0.193 ng/ml to 0.075 ng/ml [p less than or equal to 0.03]). The most dramatic effect of cetirizine was attenuation of the inflammatory cell migration into the chamber. Eosinophil infiltration was decreased by about 75% during hours 6, 7, and 8 (p less than or equal to 0.04), whereas the number of neutrophils was reduced by the same magnitude at the same times (p less than or equal to 0.04).(ABSTRACT TRUNCATED AT 250 WORDS)
一种新型H1抗组胺药西替利嗪,被用于研究其对皮肤迟发相反应(LPR)过程中介质和细胞浸润的影响。在一项双盲交叉研究中,对10名既往有皮肤LPR表现的豚草过敏受试者进行了检查。在覆盖于无顶热/抽吸诱导水疱上的皮肤小室内添加抗原或缓冲液之前2天及当天早晨,受试者每天口服一次20 mg西替利嗪或安慰剂。西替利嗪在15分钟、2小时和4小时时可使皮肤试验红斑显著减少,分别减少56%、40%和39%(均为p≤0.01),但在6小时和8小时时,皮肤红斑并未显著减轻。西替利嗪治疗未改变组胺释放,但前列腺素D2(PGD2)的产生在3至5小时达到峰值,西替利嗪治疗使其明显降低,在反应期间的所有时间点均较低;经方差分析具有显著性(p≤0.04)。在反应的第5小时抑制最为明显,此时西替利嗪使PGD2水平降低50%(从0.193 ng/ml降至0.075 ng/ml [p≤0.03])。西替利嗪最显著的作用是减轻炎症细胞向小室内的迁移。在6、7和8小时期间,嗜酸性粒细胞浸润减少约75%(p≤0.04),而中性粒细胞数量在同一时间也减少了相同幅度(p≤0.04)。(摘要截取自250字)